TRDA News and Press, Entrada Therapeutics Inc. From 05/10/23

2023-05-10 13:51:57 ET Entrada Therapeutics press release ( NASDAQ: TRDA ): Q1 GAAP EPS of -$0.21. Revenue of $25.26M. For further details see: Entrada Therapeutics GAAP EPS of -$0.21, revenue of $25.26M

- $412 million in cash, cash equivalents and marketable securities as of March 31, 2023 - - Cash runway into the second half of 2025 - BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of ...

BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointmen...

BOSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Dipal Dos...

2023-03-06 07:26:34 ET Entrada Therapeutics press release ( NASDAQ: TRDA ): Q4 GAAP EPS of -$0.79 beats by $0.04 . Cash, cash equivalents and marketable securities were $188.7 million as of December 31, 2022, compared to $215.6 million as of September 30, 2022 and...

- Established a transformative collaboration with Vertex to discover and develop intracellular Endosomal Escape Vehicle-therapeutics for myotonic dystrophy type 1 - - Actively working to resolve the clinical hold on its IND application for ENTR-601-44 - - Selected ENTR-601-45, e...

BOSTON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world’s foremost intracellular therapeutics company by establishing Endosomal Escape Vehicle (EEV™) therapeutics as a...

Entrada Therapeutics ( NASDAQ: TRDA ) closed a licensing agreement with Vertex Pharmaceuticals ( NASDAQ: VRTX ) targeting muscular disorder myotonic dystrophy type 1 (DM1) after the waiting period under the U.S. antitrust law expired. The companies had signed a collaboration a...

- Global collaboration includes ENTR-701, Entrada’s late-stage preclinical candidate for the treatment of DM1 - - Company’s cash runway extended into the second half of 2025 - BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biop...

BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the selection o...